and showed varying results. For instance, 2 separate studies performed by Karlage and colleagues, both of which analyzed content uniformity for several products obtained in Mexico, found that while the majority of the products fell within the average US Pharmacopeia (USP) limits for active pharmaceutical ingredient, individual capsules/tablets demonstrated a considerable amount of variability within the products. 10, 11 Furthermore, 2 of the 12 products tested were found to contain significantly less active pharmaceutical ingredient than the labeled amount. 10, 11 A product quality study that compared simvastatin tablets purchased from Canadian manufacturers using the Internet with the US innovator products found similar blend uniformity between the 2 groups. 12 However, a subsequent Internet simvastatin study that included a variety of international manufacturers discovered nonequivalent drug amount, tablet hardness, and weights among the samples compared with the US standard. 13 With respect to albuterol inhalers, a bioequivalence study by Leon-Molina et al of 2 brands of albuterol inhalers available in Mexican pharmacies, Ventolin ("non-US Ventolin") and Assal, demonstrated clinical differences and bioinequivalence between the 2 brands despite that both were expected to deliver 100 µg of drug per puff. 14 ) , and higher area under the percentage of response-time curve (AUC) than Assal. A proposed explanation for the discovered inequivalence in lung function tests was that there may be unaccounted pharmaceutical differences between the 2 products. 14 Pertinent pharmaceutical performance factors might include the aerosol particle size difference and actual amount of drug delivered to the lungs.
The purpose of this study is to provide some reasonable expectations for a medical tourist who shops in Mexican border towns for albuterol MDIs or for providers who encounter such a patient by comparing pharmaceutical quality and product performance of these inhalers with one another and with those available in US pharmacies.
Methods

Study Samples and Equipment
This study compared the pharmaceutical performance of albuterol MDIs obtained in the border town of Nogales, Mexico, with each other and with those available in US pharmacies. A variety of brand name products were obtained during multiple visits to Nogales pharmacies including Victory, non-US Ventolin, Assal, Xeneric-S, and Sacrusyt. Two or more units were purchased for each brand, depending on retail obtainability (more than 2 were purchased when they came in multi-packs). The samples included 5 units Xeneric-S, 2 units Victory, 3 units non-US Ventolin, 2 units Assal, and 2 units Sacrusyt, totaling 14 units. For each brand, 2 unique lot numbers were tested, with the exception of Sacrusyt, for which a second lot was unavailable at the purchase times. An evaluation of study sample product labeling is offered in Table 1 , and the units are depicted in Figure 1 . Two US innovator products, US-purchased Ventolin HFA ("US Ventolin HFA") and US-purchased Proventil ("US Proventil HFA"), were included for comparison.
Mean total dose, respirable mass, and nonrespirable mass were determined using the TSI Model 3306 Impactor Inlet (TSI Inc, Shoreview, MN). In brief, an MDI is actuated into a USP induction port ("throat"), which is coupled to the TSI 3306. The TSI 3306 is a single-stage impactor with a 4.7 µm cutpoint while the USP throat collects particles that likely would deposit in a patient's throat. A high-performance liquid chromatography (HPLC) system utilized for albuterol analysis was a 2690 separation module combined with a 996 photodiode array (Waters Corporation, Milford, MA). Pharmaceutical parameters used for comparison include the following: Procedure Every inhaler to be tested was prepared for test runs by priming with 3 actuations, washing the inhaler stem with methanol, and allowing time to dry before recording an initial weight. The TSI 3306 was prepared by adjusting the airflow to reach the manufacturer's stated calibration flow rate of 28.3 L/min. Three test runs were completed for each MDI unit and the results composited to find mean total dose, mean respirable mass, and mean nonrespirable mass per single actuation. For every test run, a standard protocol was followed in which the inhaler was actuated 5 times (shaken before each actuation) into the throat over 60 seconds. Each component of the inhaler and of the TSI 3306 that could have aerosol on it was rinsed with an appropriate volume of diluent (23:77 methanol-water), and samples were collected for the HPLC assay. These components included the throat, extension, plate, and filter from the TSI 3306 and the stem and actuator from the MDI. HPLC analysis of albuterol was performed using an Apollo C18 column (5 µm, 150 × 4.6 mm) maintained at 30 ± 2°C. The mobile phase consisted of 1% phosphoric acid-methanol (77:23), the flow rate was 0.75 mL/min, and the injection volume was 40 µL. UV detection was set at 225 nm.
Statistical Analysis
To grasp what differences, if any, there were from one consumer-available product to the next, each of the 5 Mexican border town MDI brands were compared one-on-one (Victory vs non-US Ventolin, Victory vs Assal, Victory vs Xeneric-S, etc). The continuous data of total dose and respirable mass included in each one-to-one comparison were analyzed using student's t tests. To compare the respirable mass data of each of the border town samples against each of the 2 US innovator MDI products, 1-sample t tests were performed.
Results
Visual Inspection
All 5 Mexican border town inhaler brands were sold in a Spanish-labeled box containing a single-page instructions insert. Every inhaler label displayed a visible lot number, expiration date, the international generic drug name for albuterol (salbutamol), and stated a dose of 100 µg. US Ventolin and US Proventil label the dose as 108 µg of albuterol sulfate, which correlates to 90 µg of albuterol per actuation. As illustrated in Figure 1 , the package labels of the 
Comparison of Total Dose and Respirable Mass Among Mexican Border Town Inhalers
The active drug found in all study samples was albuterol, as labeled on the packaging. However, there were pharmaceutical performance differences discovered between the Mexican border town-purchased inhalers. Figure 2 illustrates the mean total dose, mean respirable mass, and mean nonrespirable mass measured for each of these MDIs. The mean total dose was an area of significant variability among the Mexican border town products. Assal (average total dose of 57.9 µg) tested the lowest among the other 4 Mexican-purchased MDI brands (Xeneric-S 75.2 µg; Sacrusyt 66.9 µg; non-US Ventolin 66.6 µg; Victory 61.1 µg) and exhibited the widest variability ( Figure 2) . When comparing the mean total dose, only 2 comparisons showed no significant difference (Sacrusyt vs non-US Ventolin, P = .84; Victory vs Assal, P = .28). All remaining comparisons showed significant inconsistencies between the brands, suggesting that patients may encounter total dose differences from one product to the next (P < .05).
A key consideration when evaluating inhaler performance is how much of the total dose is respirable (what could reach a patient's lungs). Differences in respirable mass were also found between the Mexican border town inhaler samples. The mean respirable mass measurements of non-US Ventolin (28.0 µg) and Xeneric (28.1 µg) were the lowest compared with any of the other inhalers (Victory, 41.0 µg; Sacrusyt, 36.8 µg; Assal, 37.0 µg). When the mean respirable mass measurements of the non-US brands of albuterol MDIs were compared with one another (the mean of each brand compared with that of each of the other 4 brands), all comparisons were significantly different (P < .05) except for 2 brands (Sacrusyt vs Assal, P = .89; Xeneric-S vs non-US Ventolin, P = .98). Regarding the amount of albuterol one could expect to reach the lungs in a single puff, most of the brands tested exhibited significant differences from one another, further highlighting another aspect of product variability that a patient may encounter.
Respirable Mass: Comparison Between US Available Products and Study Samples
To examine how well a dose from a Mexican border townpurchased albuterol inhaler would reach a patient's lungs in relation to US counterpart products, respirable mass measurements of each were compared. The mean respirable mass and mean total dose of each Mexican border townpurchased MDI is displayed in conjunction with the measurements from US-purchased MDI products (Figure 3) . A 1-sample t test was used to find differences between border town inhaler results and corresponding data from US Ventolin HFA and US Proventil HFA. 15 Among the Mexican border town MDIs, all except Victory (41.0 µg) offered lower respirable mass than that of US Proventil HFA (41.5 µg) and US Ventolin HFA (37.8 µg). The respirable mass values of non-US Ventolin, Xeneric-S, and Victory were significantly different from the US Ventolin HFA (P < .001), and the values for all but Victory were different from US Proventil HFA (P < .05). More explicitly, no difference was found between Victory and US Proventil HFA (P = .06), Sacrusyt and US Ventolin HFA (P = .35), or Assal and US Ventolin HFA (P = .61). Furthermore, Victory compared significantly higher in mean respirable mass than a US branded product (Victory > US Ventolin HFA, P < .001).
Clinical Implications
A medical tourist who obtains rescue MDIs from Mexican border towns may face differences from one product to the next or differences between the border town products and the US counterparts. Expiration dates are a particular area of concern since some (but not all) inhaler units acquired in this study were short-dated as low as 1 month from purchase date. Some labeling inconsistencies among Mexican border town-purchased inhalers could be confusing for consumers, that is, some products showing safety warnings and some not. The pharmaceutical product performance examination revealed differences among the Mexican border town MDIs in total dose and respirable mass as well as differences between those products and US brand inhalers.
These differences highlight the fact that even though the labeled dose for the albuterol inhalers may be the same (100 µg for each of the Mexican inhalers), the pharmaceutical product performance is not necessarily the same. This is because the product performance (respirable and nonrespirable mass) is a function of the formulation composition as well as the metered valve size and actuator design. [16] [17] [18] Differences in these product characteristics will affect the atomization of the formulation and the resulting final aerodynamic particle size distribution. For the products tested in this study, the average weight of an actuation was different (Assal, 59.2 ± 3.8 mg; Sacrusyt, 67.8 ± 1.8 mg; Ventolin, 74.7 ± 0.9 mg; Victory, 83.3 ± 1.2 mg; Xeneric-S, 88.3 ± 3.4 mg). Thus, there are clearly differences for each product with respect to formulation and device attributes, and correspondingly, it is not surprising that there are differences in the product performance between the brands tested.
Some interesting product performance findings were uncovered in this analysis, the most important of which involved the measurement of how much drug per actuation could reach a patient's lungs (respirable mass). Several border town-purchased products performed comparably in mean respirable mass to the US innovator inhalers (Sacrusyt vs US Ventolin HFA, Assal vs US Ventolin HFA, Victory vs US Proventil HFA; P > .05). Beyond that, the Victory inhaler exhibited significantly higher mean respirable mass than the US Ventolin HFA product. Assal products performed most unpredictably having the widest range of variability in mean total dose. Finally, the non-US Ventolin product was the most expensive but did not perform the best among the border town inhalers in mean total dose and was further detected to actuate the lowest mean respirable mass of all the border town sample products.
What clinical implications these pharmaceutical differences represent are unclear. The statistical differences found seemed to point out that a patient could receive a lower dose or lower amount of respirable drug from one border town product to the next. However, the absolute differences were not so great that any product could be assumed clinically ineffective. In the United States, the 3 branded albuterol MDI products (Proventil HFA, Ventolin HFA, and ProAir HFA) are labeled with the same dose but are not considered interchangeable. If directly compared, product performance and clinical differences could be found among the 3 US brands. Yet any of those products are still considered clinically effective. In the same light, the border town products may still perform within a clinically effective range, even when statistical total dose or respirable mass differences were found.
The question regarding the spirometric differences and bioinequivalence that Leon-Molina et al found between 2 albuterol MDI products available in Mexico remains unresolved. 14 The non-US Ventolin demonstrated superior results for clinical efficacy parameters compared with that of Assal, and it was posited that pharmaceutical parameters may explain these differences. However, the pharmaceutical quality results here did not corroborate those findings. While non-US Ventolin actuation provided a higher mean total dose than that of Assal, it also delivered a significantly lower respirable mass than Assal.
Limitations
Due to travel distance, cost, and other logistics, the inhalers were only obtained from Nogales, Mexico, although it is likely that many of the brands would be found in other border towns. It may be worthwhile to test a larger number of sample inhalers, include a variety of Mexican border towns, and include Canadian products, where many Americans living in the northern United States may travel to get cheaper inhalers. In addition, while multiple lot numbers for most of the samples were tested, multiple lots of Sacrusyt inhalers were unable to be obtained due to lack of availability.
Conclusion
Mexican border town inhalers are much more affordable than the US comparatives, and as long as less expensive generic albuterol MDIs remain unavailable in the United States, some Americans are going to continue to travel to get the cheapest medications they can. Although the border townobtained inhalers varied significantly in pharmaceutical performance from one another and from US products, they still contained albuterol, the expected bronchodilator. Despite labeling differences regarding dose between the Mexican and US products, the mean respirable mass measurements (per actuation) of some of the border town inhalers were generally comparable to the US innovator MDIs. The concern is still, however, the uncertain repercussions in clinical efficacy that these differences in total dose and in respirable mass may imply. Since there was appreciable variability in the Mexican border town-obtained albuterol MDI products, clinicians and patients engaging in medical tourism should be aware of the possible differences in pharmaceutical performance and potentially therapeutic efficacy.
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